

Curriculum vitae og publikationsliste for Jens Peter Gøtze

Født i Helsingør den 11. januar 1969. Gift, to børn.

Uddannelse og akademiske grader

1987: Studentereksamen fra Holte Gymnasium.
 1997: Medicinsk kandidat fra Københavns Universitet.
 2005: Medicinsk doktorgrad ved Københavns Universitet (ISBN 87-990801-0-9).
 2008: Speciallæge i klinisk biokemi.
 2012: Adjungeret professor i kardiovaskulær endokrinologi ved Aarhus Universitet (til 2022).
 2016: Visiting Scientist ved Mayo klinikken, Rochester, USA.
 2017: Professorat ved det Sundhedsvidenskabelige Fakultet, Københavns Universitet.

Ansættelser

1993 - 1995: Skolarstipendiat, Kræftens bekæmpelse.
 1997 - 1998: Turnusansættelse, H:S Hvidovre Hospital.
 1998 - 1999: Introduktionsstilling, Klinisk Biokemisk Afdeling, H:S Rigshospitalet.
 1999 - 2000: Introduktionsstilling, Medicinsk Afdeling B, H:S Rigshospitalet.
 2000 - 2003: Klinisk assistent, H:S Rigshospitalet.
 2003 - 2005: Undervisningsstilling, Klinisk Biokemisk Afdeling, H:S Rigshospitalet.
 2005 - 2006: 1. reservelæge, Klinisk Biokemisk Afdeling, H:S Rigshospitalet.
 2006 - 2007: 1. reservelæge, Klinisk Biokemisk Afdeling, UMAS, Malmø.
 2007 - 2007: 1. reservelæge, Klinisk Biokemisk Afdeling, Rigshospitalet.
 2007 - 2008: 1. reservelæge, Klinisk Biokemisk Afdeling, Bispebjerg Hospital.
 2008 - 2009: Afdelingslæge, Klinisk Biokemisk Afdeling, Rigshospitalet.
 2007 - 2014: Ekstern lektor ved det Sundhedsvidenskabelige Fakultet, Københavns Universitet.
 2013 - 2017: Forskningsansvarlig konsulent ved professionshøjskolen Metropol.
 2009 -: Overlæge, Klinisk Biokemisk Afdeling, Rigshospitalet.
 2015 -: Uddannelsesansvarlig overlæge, Klinisk Biokemisk Afdeling, Rigshospitalet.
 2017 -: Assisterende redaktør ved Ugeskrift for læger.

Forskningsproduktion

December 2018: I alt 288 publikationer bestående af 185 originalarbejder, 42 oversigtsartikler og letters, 16 editorials, 9 bogkapitler og 36 andre publikationer. Herfra er 59 artikler som førsteforfatter, 58 som sidsteforfatter, og 24 som eneforfatter. Samlet antal citationer 4000, gennemsnitlig citation 14.2; H-indeks (Web of Science) = 31.

Ledelse og administration

Fra 2009 ansvarlig for Klinisk Biokemisk Afdelings koagulationslaboratorium på Rigshospitalet. Laboratoriet betjener Østdanmark med højt specialiserede analyser for blødersygdomme samt på regionsniveau for tromboserelaterede sygdomme, herunder genetisk udredning af sjældne hæmostaseforstyrrelser. Funktionen forudsætter tæt samarbejde med en klinisk enhed på Rigshospitalet for samme. Fra 2011 økonomisk ansvarlig for afdelingens peptidforskningssektion, som aktuelt består af tre professorer, en overlæge, postdocs, ph.d.-studerende, specialestuderende og bioanalytikere. Lederuddannelse (ledelse af medarbejdere) via Region H (1 årigt kursus) samt forskningsledelse (0,5 årigt kursus). Indstillet 2013 af sektionens ansatte til Region Hovedstadens lederpris.

Undervisning og pædagogik

- Underviser i makroskopisk anatomi for læge- og tandlægestuderende ved Københavns Universitet (1994-1996).

- Anatomiunderviser ved optræningscentret i Karlslunde (1999-).
- Undervisning af medicinstuderende (1999-) og A-kursister i klinisk biokemi (2006-).
- Prægraduat undervisning af medicinstuderende ved Københavns Universitet (stedfortræder for tre af Klinisk Biokemisk Afdelings professorer) med emner i endokrinologi samt trombose og hæmostase (2009-).
- Underviser ved ph.d.-kurser i kardiologi og klinisk biokemi ved henholdsvis Aarhus og Københavns Universitet (2009-).
- Voksenpædagogisk kursus (1 uge).
- Underviser på kursus i forskningsformidling, Region H (2015-).
- Hovedansvarlig for årligt ph.d.-kursus ved Københavns Universitet i videnskabelig præsentation (2012-).

Bestyrelsesposter

- Bestyrelsesmedlem i Øfeldt Centret (2010-).
- Bestyrelsesmedlem i Warwara Larsens Fond (2016-).

Videnskabelig vejleder

Aktuelt vejleder for fem ph.d.-studerende, tre kommende ph.d.-studerende, læger under uddannelse, samt to læger med ph.d.-baggrund og kommende disputats. Har gennemført "SUND Seminar on Responsible Conduct of Research" for ph.d.-vejledere (2015).

- Vejleder for ph.d.-stud. Dijana Terzic (2015-). Projektet omhandler natriuretiske peptider og mave-tarm kanalens hormoner.
- Vejleder for ph.d.-stud. Christina Kjær (2015-). Projektet omhandler molekylær karakterisering af humant epilepsivæv.
- Vejleder for ph.d.-stud. Lasse Holst Hansen (2016-). Projektet omhandler post-translational modifikation af natriuretiske peptider.
- Vejleder for ph.d.-stud. Rune Strandby (2016-). Projektet omhandler proANP i plasma som markør for væsketerapi ved kirurgi.
- Vejleder for ph.d.-stud. Mads Møller Foged (2018-). Projektet omhandler lipidprofiler ved kræftsygdomme.

Tidligere vejleder for ph.d.-afhandlinger, kandidatopgaver og postdocs ved det Sundhedsvidenskabelige Fakultet i København og ved Aarhus Universitet:

- Projektvejleder for Søren Junge Nielsen (ph.d.-afhandling forsvaret 2008). Projektet omhandlede C-type natriuretisk peptid, metodeudvikling, karakterisering af vævsekspression, samt proCNP som biomarkør ved prostatakræft. I alt seks artikler er publiceret fra det forløb med projektvejleder som sidsteforfatter.
- Projektvejleder for Maren Skau (ph.d.-afhandling forsvaret 2010). Projektet omhandlede natriuretiske peptider i cerebrospinalvæske ved idiopatisk, forhøjet intrakranielt tryk. I alt en artikel er publiceret med projektvejleder som medforfatter.
- Projektvejleder for Birgitte Kousholt (ph.d.-afhandling forsvaret 2012). Projektet omhandlede natriuretiske peptider i kardioprotektion. I alt to artikler er publiceret fra det forløb med projektvejleder som sidsteforfatter.
- Hovedvejleder for Julie Smith (ph.d.-afhandling forsvaret 2012). Projektet omhandlede natriuretiske peptider i neonatologi og medfødt hjertesygdom. I alt fem artikler er publiceret fra det forløb med hovedvejleder som sidsteforfatter på tre arbejder.
- Projektvejleder for Ingrid Hunter (ph.d.-afhandling forsvaret 2013). Projektet omhandlede natriuretiske peptider i forsøgsdyr og ved hjertesygdom. I alt tre artikler er publiceret fra det forløb med projektvejleder som sidsteforfatter og sidenhen syv artikler mere.
- Hovedvejleder for Solvej Lippert (ph.d.-afhandling forsvaret 2014). Projektet omhandlede C-type natriuretisk peptid i urogenital sygdom, herunder prostatakræft. I alt tre artikler er publiceret fra det forløb med hovedvejleder som sidsteforfatter.

- Hovedvejleder for Annette Timm (kandidatopgave forsvaret 2013). Projektet omhandlede nye diagnostiske muligheder ved von Willebrands sygdom. I alt fem artikler er publiceret fra det forløb med hovedvejleder som sidsteforfatter på fire arbejder.
- Hovedvejleder for Lasse Holst Hansen (kandidatopgave forsvaret 2014). Projektet omhandlede glykosylering i hjertet med fokus på natriuretiske hormoner. I alt to artikler er publiceret fra det forløb med hovedvejleder som sidsteforfatter (forløb stadig i gang).
- Hovedvejleder for Dijana Terzic (kandidatopgave forsvaret 2015). Projektet omhandlede relationen mellem insulin og hjerte ANP. I alt to artikler + et bogkapitel er publiceret fra det forløb med flere artikler under udarbejdelse.
- Hovedvejleder for Kathrine Overgaard Foss Jensen (kandidatopgave forsvaret 2016). Projektet omhandlede analyser for "nye" antikoagulerende lægemidler. I alt en originalartikel herfra med hovedvejleder som sidsteforfatter.
- Vejleder for ph.d.-stud. Qasam Ghulam (ph.d.-afhandling forsvaret 2018). Projektet omhandlede sammenhængen mellem trombose og biomarkører ved aortaaneurismer. I alt en originalartikel med vejleder som medforfatter.
- Vejleder for ph.d.-stud. Bjarke Follin Larsen (ph.d.-afhandling forsvaret 2018). Projektet omhandlede behandling med stamceller i klinisk kardiologi. I alt en originalartikel med vejleder som medforfatter.
- Supervisor for postdoc Jakob Albrethsen (2014 - 2016).
- Supervisor for postdoc Ewa Soltysinska (2014 - 2015).
- Supervisor for postdoc Nora Zois (2012 - 2016).
- Supervisor for postdoc Julie Smith (2012 - 2016).

Tidligere vejleder for fire skolarstipendiater:

- Stud.med. Anders Hejmdal Poulsen (natriuretiske peptider og kardiogen shock).
- Stud.med. Jesper Madsen (natriuretiske peptider og post-translationel processering).
- Stud.med. Louise Honoré (oprensning af humant N-terminalt proBNP).
- Stud.med. Signe Eiland (gastrin i ventrikelkræft).

Tidligere vejleder for forskningsårsstuderende, stud.med. Martin Frydland (kromogranin A ved akut myokardieinfarkt). Desuden vejleder for otte OSVAL 2 opgaver (stud.med. Anders Hejmdal Poulsen, stud.med. Jesper Madsen, stud.med. Louise Honoré, stud.med. Casper Bang, stud.med. Martin Andersen, stud.med. Camilla Bardram Johnbeck, stud.med. Ida Willer, stud.med. Kirstine Pilgaard Lærum).

Aktuelt vejleder for 6 bachelorstuderende (Terese Bugge, Filip Davidovski, Steven Nybo, Simon Larsen, Kasper Holst Axelsen, Lukas Posthuma) og to kandidatstuderende (Ulrik Larsen, Amalie Jestung).

Videnskabelige indstillinger

- Indstillet Christina Christoffersen til Jakobinermedaljen 2013.
- Indstillet Dijana Terzic til årets bioanalytikerpris 2015.
- Indstillet Øfeldt Centret til Vanførefondens Forskerpris 2016.
- Indstillet forskere til Nobelprisen i medicin og fysiologi 2016 efter invitation fra akademiet.

Priser

- Vinder af foredragskonkurrence for yngre kardiologer i Norden (XIX Nordic Congress of Cardiology, Odense 2003; *Ugeskr Laeger* 2003;**165**:2923), samt 2. plads i Astrup konkurrencen (Nordisk Kongres i Klinisk Kemi, Malmø 2004; *Klinisk Kemi i Norden* 2004;**16**:8-12).
- Tildelt Christenson-Cesons legat (2006).
- Tildelt Jakobinermedaljen af Selskabet for Teoretisk og Anvendt Medicin (2008).
- Tildelt Odd Fellow Ordenens Forskerpris (2014).

Videnskabelig bedømmer

- Bedømmer på Sundhedsvidenskabelig ph.d.-afhandling ved Københavns Universitet (cand.med. Tue Christoffersen, marts 2007).
- Opponent på sundhedsvidenskabelig doktorafhandling ved Lunds Universitet, Sverige (Cecilia Oslakovic, juni 2010).
- Bedømmer på lektorat ved medicinsk forskningslaboratorium, Institut for Klinisk Medicin, Health, Aarhus Universitet (juni 2012).
- Bedømmer på forskningsprofessorat ved Medical School, University of Otago, Christchurch, New Zealand (august 2012).
- Bedømmer på sundhedsvidenskabelig ph.d.-afhandling ved Syddansk Universitet (cand.scient.pharm. Helene Skjøtt-Arkil, april 2013).
- Bedømmer på sundhedsvidenskabelig doktordisputats ved Oslos Universitet, Norge (cand.med. Erik Tandberg Askevold, juli 2013).
- Bedømmer på ph.d.-afhandling ved University of Otago, New Zealand (Mauthri J Siriwardena, august 2013).
- Bedømmer på bachelorprojekt ved Københavns Universitet (Thomas D. Madsen, juni 2015).
- Bedømmer på ph.d.-afhandling ved University of Gent, Belgien (Nicky Van Der Vekens, juni 2015).
- Bedømmer på ph.d.-afhandling ved Københavns Universitet (Signe Torøng, august 2015).
- Reviewer (n = 154) på manuskripter for internationale tidsskrifter inkl. *The Lancet*, *European Heart Journal*, *American Journal of Physiology*, *Clinical Chemistry*, *FASEB Journal*, *Journal of the American College of Cardiology*, *Circulation* og *Circulation Research*.

Editor-funktioner, arrangerede møder

- Arrangør af seminar om natriuretiske peptider (København 2002) og Klinisk Biokemisk Årsmøde (København 2003). Medredaktør for Dansk Selskab for Klinisk Biokemis medlemsblad (2005 - 2007).
- Initiativtager til og arrangør af "Båstad" seminaret om kardiovaskulær endokrinologi (2009-).
- Initiativtager til og arrangør af "The Abildgaard Symposium 2010: Mammalian Cardiovascular Endocrinology". Et samarbejde mellem Rigshospitalet og KU-LIFE, København.
- Chair for "The 19th International Symposium on Regulatory Peptides, Copenhagen, 2012.
- Medlem af *Nordic Hemophilia Council*, NCG (2008 -).
- Medlem af Editorial Board: *Biomarkers in Medicine* (2009 -).
- Medlem af Editorial Board: *Journal of Pediatric Biochemistry* (2009 -).
- Medlem af Editorial Board: *Journal of Geriatric Cardiology* (2010 -).
- Medlem af Editorial Board: *Journal of Biomarkers* (2012 -).
- Medlem af Editorial Board: *Research Journal of Endocrinology and Metabolism* (2013 -).
- Medlem af Editorial Board: *Peptides* (2014 - 2016).
- Medlem af Editorial Board: *Frontiers in Cardiovascular Medicine* (2015 -).
- Associate Editor: *Cardiovascular Endocrinology* (2012 -).

Faglige aktiviteter

- Tillidsrepræsentant i 2½ år for yngre læger på Rigshospitalet. Gennemført uddannelsen som tillidsrepræsentant (FAYL kursus I+II).
- Udpeget af Dansk Selskab for Klinisk Biokemi og uddannet af Sundhedsstyrelsen til inspektør for de diagnostiske specialer (2010-2017).

Kurser

Deltaget i eksterne kurser om kardiologiske emner samt A-kurser under hoveduddannelsen i klinisk biokemi. Bestået FELASA C-kursus = selvstændig tilladelse til dyreforsøg.

Eksterne bevillinger de sidste 10 år

2008: 200.000 kr. fra Lundbeckfonden.
 2009: 500.000 kr. fra Lundbeckfonden.
 2009: 150.000 kr. fra P.A. Messerschmidtfonden.
 2009: 125.000 kr. fra Eva og Henry Frænkels Mindefond.
 2010: Rammebevilling fra Rigshospitalets forskningsråd (3 x 300.000 kr.).
 2010: 750.000 kr. fra Lundbeckfonden.
 2012: Rammebevilling fra Novo Nordisk fonden (5 x 1.000.000 kr.).
 2013: 30.000 kr. fra Snedkermester Sophus Jacobsen og hustru Astrid Jacobsens Fond.
 2013: 1.463.000 kr. fra Region Hovedstaden.
 2014: 100.000 kr. fra Arvid Nilssons Fond.
 2014: 200.000 kr. fra Toyota-Fonden.
 2015: 300.000 kr. fra Diagnostisk Center, Rigshospitalet (samfinansiering af ph.d. forløb).
 2015: 1.250.000 kr. fra den internationale KFJ pris (sammen med Mayoklinikken, USA).

Videnskabeligt samarbejde

- På nationalt plan samarbejde med forskningsledere i egen afdeling samt på Rigshospitalet (professorer Lars Køber, Jens Kastrup og Jesper Hastrup Svendsen, samt overlæge Finn Gustafsson). Desuden samarbejde med professor Jan Skov Jensen (Gentofte Hospital), professor Søren Møller (Hvidovre Hospital), professor Jørgen Jeppesen (Glostrup Hospital), professor Michael Hasenkam (Skejby Hospital), og professor Jan Fahrenkrug (Bispebjerg Hospital).
- Internationale samarbejder med professor John Burnett Jr. (Mayo klinikken, USA), samt professorerne Fred Apple (Minnesota University, USA), Gary Baxter (Cardiff University, UK), Leo Dunkel (Oulu University, Finland) og Mark Richards (Otago University, New Zealand).

Forskningsvision

Min vision er konsolidering af *kardiovaskulær endokrinologi* som en tværfaglig disciplin med udgangspunkt i innovative biokemiske og molekylærbiologiske metoder for relevante peptidsystemer. Arbejdet baseres på biokemisk metodologi, eksperimentelle modeller for human hjertesygdom, samt afprøvning i kliniske studier. Emnet er per definition tværfagligt og kræver et tæt samarbejde med basalforskere og klinikere. Helt overordnet er målet at kunne bidrage til ny erkendelse af endokrine sammenhænge ved human hjertesygdom og mulighed for nye diagnostiske og terapeutiske tiltag.

Publikationsliste

I. Originalarbejder (185)	7
II. Oversigtsartikler & letters (42).....	21
III. Editorials (16)	24
IV. Bogkapitler (9).....	25
V. Andre publikationer (20)	26
VI. Indlæg (16).....	28
VII. Patentansøgninger (3).....	29
VIII. Udarbejdede eller indsendte manuskripter	30

Det totale antal publikationer er 288. Tallene i parentes angiver antal publikationer pr. kategori. Abstracts er ikke inkluderet.

I. Originalarbejder (185)

1. **Gøtze JP**, Lindeskog P, Törnquist CSI. Effects of induction and age-dependent enzyme expression on lung bioavailability, metabolism, and DNA binding of urban air particulate-absorbed benzo[a]pyrene, 2-nitrofluorene, and 3-amino-1,4-dimethyl-5H-pyridol-(4,3)-indole. *Environ Health Perspect* 1994;**102** Suppl 4:147-156.
2. **Gøtze JP**, Rehfeld JF. Displaced chromatographic elution of gastrin-17 in normal human serum. *Scand J Clin Lab Invest* 1994;**54**:673-676.
3. Hansen CP, **Gøtze JP**, Stadil F, Rehfeld JF. Excretion of progastrin products in human urine. *Am J Physiol* 1999;**276**:G985-G992.
4. **Gøtze JP**, Jensen CH. Follow-up of volar plate interposition arthroplasty (Tupper) of the metacarpophalangeal joints in rheumatoid hands: Preliminary findings. *Scand J Plast Reconstr Surg Hand Surg* 2000;**34**:249-251.
5. Hansen CP, **Gøtze JP**, Stadil F, Rehfeld JF. The metabolism of gastrin-52 and gastrin-6 in pigs. *Am J Physiol Gastroenterol Liver Physiol* 2000;**279**:G552-560.
6. **Gøtze JP**, Nielsen FC, Burcharth F, Rehfeld JF. Closing the gastrin loop in pancreatic carcinoma – coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma. *Cancer* 2000;**88**:2487-2494.
7. **Gøtze JP**, Thorsen S, Haunsø S. Erhvervet warfarinresistens hos en patient med mekanisk mitralklap. *Ugeskr Laeger* 2001;**163**:7075-7076.
8. **Gøtze JP**, Kastrop J, Pedersen F, Rehfeld JF. Quantification of Pro-B-Type Natriuretic Peptide and its products in Human plasma by use of an analysis independent of precursor processing. *Clin Chem* 2002;**48**:1035-1042.
9. Christoffersen C, **Gøtze JP**, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, Rolin B, Nielsen LB. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. *Hypertension* 2002;**40**:54-60.
10. Konturek PC, Bielanski W, Konturek SJ, Hartwich A, Pierzhalski P, Duda A, Karczewska E, Marlicz M, Starzynska T, Lawniczak M, Darasz Z, **Gøtze JP**, Rehfeld JF, Hahn EG. Progastrin and cyclooxygenase-2 in colorectal cancer. *Dig Dis Sci* 2002;**47**:1984-1991.
11. **Gøtze JP**, Rehfeld JF. Impact of assay epitope specificity in gastrinoma diagnosis. *Clin Chem* 2003;**49**:333-334.
12. **Gøtze JP**, Christoffersen C, Perko M, Arendrup H, Rehfeld JF, Kastrop J, Nielsen LB. Increased cardiac BNP gene expression associated with myocardial ischemia. *FASEB J* 2003;**17**:1105-1107. Epub 2003 Apr 22 (10.1096/fj.02-0796fje).
13. Konturek SJ, Gonciarz M, Gonciarz Z, Bielanski W, Mazur W, Mularczyk A, Konturek PC, **Gøtze JP**, Rehfeld JF. Progastrin and its products from patients with chronic viral hepatitis and liver cirrhosis. *Scand J Gastroenterol*, 2003;**38**:643-647.
14. Christoffersen C, Bollano E, Lindegaard MLS, Bartels ED, **Gøtze JP**, Andersen CB, Nielsen LB. Cardiac lipid accumulation associated with diastolic dysfunction in obese mice. *Endocrinology* 2003;**144**:3483-3490.
15. Henriksen JH, **Gøtze JP**, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in

patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. *Gut* 2003;**52**:1511-1517.

16. Konturek SJ, Konturek PC, Bielanski W, Karczewska E, Zuchowicz M, Hartwich A, Rehfeld JF, **Gøtze JP**, Hahn EG. Serum progastrin and its products, gastric acid secretion and serum pepsinogen I in gastric cancer. *Digestion* 2003;**68**:169-177.
17. **Gøtze JP**, Henriksen JH, Fuglsang S, Christensen E, Bendtsen F, Møller S. Cirrotisk kardiomyopati: øget cirkulerende pro-brain-natriuretisk peptid og brain-natriuretisk peptid ved cirrose. *Ugeskr Laeger* 2004;**166**:2999-3002 (parallelpublikation).
18. **Gøtze JP**, Videbæk R, Boesgaard S, Aldershvile J, Rehfeld JF, Carlsen J. Pro-brain natriuretic peptide as marker of cardiovascular or pulmonary causes of dyspnea in patients with terminal parenchymal lung disease. *J Heart Lung Transplant* 2004;**23**:80-87.
19. **Gøtze JP**, Wang Y, Rehfeld JF, Jørgensen E, Kastrup J. Coronary angiography transiently increases plasma pro-B-type natriuretic peptide. *Eur Heart J* 2004;**25**:759-764.
20. **Gøtze JP**, Gore A, Møller CH, Steinbrüchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. *FASEB J* 2004;**18**:1928-1930. Epub 2004 Sept 22 (10.1096/fj.03-1336fje).
21. **Gøtze JP**, Rehfeld JF, Videbæk R, Friis-Hansen L, Kastrup J. B-type natriuretic peptide and its precursor in cardiac venous blood from failing hearts. *Eur J Heart Fail* 2005;**7**:69-74.
22. Wang YZ, **Gøtze JP**, Videbæk R, Rehfeld JF, Kastrup J. Increased circulating endothelins are not of cardiopulmonary origin in heart failure patients. *Scand J Clin Lab Invest* 2005;**65**:341-347.
23. **Gøtze JP**, Paloheimo LI, Linnala A, Sipponen P, Hansen CP, Rehfeld JF. Gastrin-17 specific antibodies are too specific for gastrinoma diagnosis but stain G-cells. *Scand J Gastroenterol* 2005;**40**:596-598.
24. Halse KG, Lindegaard MLS, **Gøtze JP**, Damm P, Mathiesen ER, Nielsen LB. Increased plasma pro-B-type natriuretic peptide in infants of women with type I diabetes. *Clin Chem* 2005;**51**:2296-2302.
25. Nielsen SJ, Rehfeld JF, Pedersen F, Kastrup J, Videbæk R, **Gøtze JP**. Measurement of pro-C-type natriuretic peptide in plasma. *Clin Chem* 2005;**51**:2173-2176.
26. **Gøtze JP**, Jensen G, Møller S, Bendtsen F, Rehfeld JF, Henriksen JH. BNP and N-terminal pro-BNP are both extracted in the normal kidney. *Eur J Clin Invest* 2006;**36**:8-15.
27. **Gøtze JP**, Hansen CP, Rehfeld JF. Antral content, secretion and peripheral metabolism of N-terminal progastrin fragments. *Regul Pept* 2006;**133**:47-53.
28. **Gøtze JP**, Rehfeld JF, Carlsen J, Videbæk R, Andersen CB, Boesgaard S, Friis-Hansen L. Apelin: A new plasma marker of cardiopulmonary disease. *Regul Pept* 2006;**133**:134-138.
29. Runge M, Hughes P, **Gøtze JP**, Petersen R, Steinbrüchel DA. Evaluation of myocardial metabolism with microdialysis after protection with cold blood- or crystalloid cardioplegia. A porcine model. *Scand Cardiovasc J* 2006;**40**:186-193.
30. **Gøtze JP**, Møgelvang R, Måge L, Scharling H, Schnohr P, Søgaard P, Rehfeld JF, Jensen JS. Plasma pro-B-type natriuretic peptide in the general population: screening for left ventricular hypertrophy and systolic dysfunction. *Eur Heart J* 2006;**27**:3004-3010.

31. Hejmdal A, Boesgaard S, Lindholm MG, **Gøtze JP**. B-type natriuretic peptide and its molecular precursor in myocardial infarction complicated by cardiogenic shock. *J Card Fail* 2007;**13**:184-188.
32. Nybo M, Nielsen LB, Nielsen SJ, Lindegaard MLS, Damm P, Rehfeld JF, **Gøtze JP**. Discordant expression of pro-B-type and pro-C-type natriuretic peptide in newborn infants of mothers with type 1 diabetes. *Regul Pept* 2007;**141**:135-139.
33. Damgaard M, **Gøtze JP**, Norsk P, Gadsbøll N. Altered sodium intake affects plasma concentrations of BNP but not proBNP in healthy subjects and patients with compensated heart failure. *Eur Heart J* 2007;**28**:2726-2731.
34. Ripa RS, Wang Y, **Gøtze JP**, Jørgensen E, Johnsen HE, Kastrup J. Circulating angiogenic cytokines and stem cells in patients with severe chronic ischemic heart disease — Indicators of myocardial ischemic burden? *Int J Cardiol* 2007;**120**:181-187.
35. Alehagen U, **Gøtze JP**, Dahlström U. Reference intervals and decision limits for B-type natriuretic peptide (BNP) and its precursor (Nt-proBNP) in the elderly. *Clin Chim Acta* 2007;**382**:8-14.
36. Nybo M, Benn M, Møgelvang R, Jensen JS, Schnohr P, Rehfeld JF, **Gøtze JP**. Impact of hemoglobin on plasma pro-B-type natriuretic peptide concentrations in the general population. *Clin Chem* 2007;**53**:1921-1927.
37. Møgelvang R, **Gøtze JP**, Schnohr P, Lange P, Sogaard P, Rehfeld JF, Jensen JS. Discriminating between cardiac and pulmonary dysfunction in the general population with dyspnea by plasma pro-B-type natriuretic peptide. *J Am Coll Cardiol* 2007;**50**:1694-1701.
38. Nielsen SJ, Rehfeld JF, **Gøtze JP**. Mismeasure of C-type natriuretic peptide. *Clin Chem* 2008;**54**:225-227.
39. Nielsen SJ, **Gøtze JP**, Jensen H, Rehfeld JF. ProCNP and CNP are expressed primarily in male genital organs. *Regul Pept* 2008;**146**:204-212.
40. Møller CH, Nørgaard MA, **Gøtze JP**, Andersen CB, Olsen VN, Steinbrüchel DA. Selective retrograde venous revascularization of the myocardium when PCI or CABG is impossible: investigation in a porcine model. *Heart Surg Forum* 2008;**11**:E99-104.
41. Friis-Hansen L, Sælsen L, Abildstrøm SZ, **Gøtze JP**, Hilsted LM. An algorithm for applying flagged Sysmex XE-2100 absolute neutrophil counts in clinical practice. *Eur J Haematol* 2008;**81**:140-153.
42. **Gøtze JP**, Dahlström U, Rehfeld JF, Alehagen U. Impact of epitope specificity and precursor maturation in pro-B-type natriuretic peptide measurement. *Clin Chem* 2008;**54**:1780-1787.
43. Christiansen MS, Iversen K, Larsen CT, **Gøtze JP**, Hommel E, Mølviig J, Pedersen BK, Magid E, Feldt-Rasmussen B. Increased urinary orosomucoid excretion: a proposed marker for inflammation and endothelial dysfunction in patients with type 2 diabetes. *Scand J Clin Lab Invest* 2009;**69**:272-281.
44. Poulsen TD, Andersen LW, Steinbrüchel D, **Gøtze JP**, Jørgensen OS, Olsen NV. Two large preoperative doses of erythropoietin do not reduce the systemic inflammatory response to cardiac surgery. *J Cardiothorac Vasc Anesth* 2009;**23**:316-323.
45. Nielsen SJ, Iversen P, Jensen H, Rehfeld JF, **Gøtze JP**. C-type natriuretic peptide in prostate cancer. *APMIS* 2009;**117**:60-67.

46. Møgelvang R, Søgaard P, Pedersen SA, Olsen NT, Marott JL, Schnohr P, **Gøtze JP**, Jensen JS. Cardiac dysfunction assessed by echocardiographic tissue Doppler imaging is an independent predictor of mortality in the general population. *Circulation* 2009;**119**:2679-2685.
47. Møgelvang R, **Gøtze JP**, Pedersen SA, Olsen NT, Marrot JL, Schnohr P, Søgaard P, Jensen JS. Preclinical systolic and diastolic dysfunction assessed by tissue doppler imaging is associated with elevated plasma pro-B-type natriuretic peptide concentrations. *J Card Fail* 2009;**15**:489-495.
48. Schou M, Alehagen U, **Gøtze JP**, Gustafsson F, Dahlström U. Effect of estimated glomerular filtration rate on plasma concentrations of B-type natriuretic peptides measured with multiple immunoassays in elderly individuals. *Heart* 2009;**95**:1514-1519.
49. Nilsson B, **Gøtze JP**, Chen X, Pehrson S, Svendsen JH. Increased NT-pro-B-type natriuretic peptide independently predicts outcome following catheter ablation of atrial fibrillation. *Scand J Clin Lab Invest* 2009;**69**:843-850.
50. Pecini R, Hammer-Jensen S, Dalsgaard M, **Gøtze JP**, Hassager C, Køber L. Determinants of exercise-induced increase of mitral regurgitation in patients with acute coronary syndromes. *Echocardiography* 2010;**27**:567-574.
51. **Gøtze JP**, Georg B, Jørgensen HL, Fahrenkrug J. Chamber-dependent circadian expression of cardiac natriuretic peptides. *Regul Pept* 2010;**160**:140-145.
52. Skau M, **Gøtze JP**, Rehfeld JF, Jensen R. Natriuretic pro-peptides in idiopathic intracranial hypertension. *Regul Pept* 2010;**164**:71-77.
53. Bonfils PK, Damgaard M, Taskiran M, **Gøtze JP**, Norsk P, Gadsbøll N. Impact of diuretic treatment and sodium intake on plasma volume in patients with compensated systolic heart failure. *Eur J Heart Fail* 2010;**12**:995-1001.
54. Bartels EM, Nielsen JM, Bisgaard LS, **Gøtze JP**, Nielsen LB. Decreased expression of natriuretic peptides associated with lipid accumulation in cardiac ventricle of obese mice. *Endocrinology* 2010;**151**:5218-5225.
55. Lippert SK, Rehfeld JF, **Gøtze JP**. Processing-independent analysis for pro-C-type natriuretic peptide. *J Immunol Methods* 2010;**362**:32-37.
56. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Prognostic assessment of elderly patients with symptoms of heart failure by combining high-sensitivity troponin T and N-terminal pro-B-type natriuretic peptide measurements. *Clin Chem* 2010;**56**:1718-1724.
57. Mygind ND, Harutyunyan MJ, Mathiasen AB, Ripa RS, Thune JJ, **Gøtze JP**, Johansen JS, Kastrup J, The CLARICOR Trial Group. The influence of statin treatment on the inflammatory biomarkers YKL-40 and HsCRP in patients with stable coronary artery disease. *Inflamm Res* 2011;**60**:281-287.
58. Harutjunyan MJ, Mathiasen AB, Winkel P, **Gøtze JP**, Hansen JF, Hildebrandt P, Jensen GB, Hilden J, Jespersen CM, Kjølner E, Kolmos, HJ, Gluud C, Kastrup J, CLARICOR Trial Group. High-sensitivity C-reactive protein and N-terminal pro-B-type natriuretic peptide in patients with stable coronary artery disease: a prognostic study within the CLARICOR Trial. *Scand J Clin Lab Invest* 2011;**71**:52-62.
59. Hermann TS, Dall CH, Christensen SB, **Gøtze JP**, Prescott E, Gustafsson F. Effect of high intensity exercise on peak oxygen uptake and endothelial function in long-term heart transplant recipients. *Am J Transplant* 2011;**11**:536-541.

60. Olsen NT, Sogaard P, Larsson HBW, **Gøtze JP**, Jons C, Mogelvang R, Nielsen OW, Fritz-Hansen T. Speckle-tracking echocardiography for predicting outcome in chronic aortic regurgitation during conservative management and after surgery. *JACC Cardiovasc Imaging* 2011;**4**:223-230.
61. Passino C, Franzino E, Giannoni A, Prontera C, **Gøtze JP**, Emdin M, Clerico A. B-type natriuretic peptide secretion following scuba diving. *Biomark Med* 2011;**5**:205-209.
62. Sennels HP, Jørgensen HL, Hansen AL, **Gøtze JP**, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: The Bispebjerg study of diurnal variations. *Scand J Clin Lab Invest* 2011;**71**:532-541.
63. Rehfeld JF, Gingras MH, Bardram L, Hilsted L, **Gøtze JP**, Poitras P. The Zollinger-Ellison syndrome and mismeasurement of gastrin. *Gastroenterology* 2011;**140**:1444-1453.
64. Hunter I, Alehagen U, Dahlström U, Rehfeld JF, Crimmins DL, **Gøtze JP**. N-terminal pro-atrial natriuretic peptide measurement in plasma suggests covalent modification. *Clin Chem* 2011;**57**:1327-1330.
65. Hunter I, Rehfeld JF, **Gøtze JP**. Measurement of the total proANP product in mammals by processing independent analysis. *J Immunol Methods* 2011;**370**:104-110.
66. Mathiasen AB, Harutyunyan MJ, Jørgensen E, Helqvist S, Ripa R, **Gøtze JP**, Johansen JS, Kastrup J. Plasma YKL-40 in relation to the degree of coronary artery disease in patients with stable ischemic heart disease. *Scand J Clin Lab Invest* 2011;**71**:439-447.
67. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Association of copeptin and N-terminal proBNP concentrations to risk of cardiovascular death in elderly patients with symptoms of heart failure. *JAMA* 2011;**305**:2088-2095.
68. Carlsen CM, Bay M, Kirk V, **Gøtze JP**, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. *Eur J Heart Fail* 2012;**14**:240-247.
69. Sennels HP, Jørgensen HL, **Gøtze JP**, Fahrenkrug J. Rhythmic 24-hour variations of frequently used clinical biochemical parameters in healthy young males – The Bispebjerg study of diurnal variations. *Scand J Clin Lab invest* 2012;**72**:287-295.
70. Husby S, Lind B, **Gøtze JP**. Practical use of natriuretic peptide measurement: questionnaire results from general practitioners and cardiologists. *Biomark Med* 2012;**6**:13-18.
71. Carlsen CM, Bay M, Kirk V, **Gøtze JP**, Køber L, Nielsen OW. Prevalence and prognosis of heart failure with preserved ejection fraction and elevated N-terminal pro brain natriuretic peptide: a 10-year analysis from the Copenhagen Hospital Heart Failure Study. *Eur J Heart Fail* 2012;**14**:240-247.
72. Smith J, **Gøtze JP**, Sondergaard L, Kjaergaard J, Iversen KK, Vejlsstrup NG, Hassager C, Andersen CB. Myocardial hypertrophy after pulmonary regurgitation and valve implantation in pigs. *Int J Cardiol* 2012;**159**:29-33.
73. Kilpeläinen L, Ivaska KK, Kuiri-Hänninen T, Väänänen HK, Rehfeld JF, **Gøtze JP**, Sankilampi U, Dunkel L. Urinary osteocalcin and serum pro-C-type natriuretic peptide predict linear catch-up growth in infants. *J Bone Miner Res* 2012;**27**:1528-1535.

74. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, **Gøtze JP**, Hildebrandt P, Gustafsson F. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. *J Card Fail* 2012;**18**:351-358.
75. Egstrup M, Schou M, Tuxen CD, Kistorp CN, Hildebrandt PR, Gustafsson F, Faber J, **Gøtze JP**, Gustafsson I. Prediction of outcome by highly sensitive troponin-T in outpatients with chronic systolic left ventricular heart failure. *Am J Cardiol* 2012;**110**:552-557.
76. Munk M, Memon AA, **Gøtze JP**, Nielsen LB, Nexø E, Sørensen BS. Hypoxia changes the expression of the epidermal growth factor (EGF) system in human hearts and in cultured cardiomyocytes. *PLoS One* 2012;**7**:e40243.
77. Kousholt BS, Larsen JKR, Bisgaard L, Burnett JC Jr, Hasenkam JM, **Gøtze JP**. Natriuretic peptide infusion reduces myocardial injury during acute ischemia/reperfusion. *Cardiovasc Endocrinol* 2012;**1**:4-12.
78. Terzic D, Johansson-Fällgren AS, Ragnarsson O, **Gøtze JP**, Hammarsten O. Evaluation of a sensitive copeptin assay for clinical measurement. *Open Clin Chem J* 2012;**5**:21-26.
79. Møller S, Mortensen C, Bendtsen F, Jensen LT, **Gøtze JP**, Madsen JL. Cardiac sympathetic imaging with *mIBG* in cirrhosis and portal hypertension: relation to autonomic and cardiac function. *Am J Physiol Gastrointest Liver Physiol* 2012;**303**:G1228-1235.
80. **Gøtze JP**, Jørgensen HL, Sennels HP, Fahrenkrug J. Diurnal plasma concentrations of natriuretic propeptides in healthy young males. *Clin Chem* 2012;**58**:789-792.
81. Alehagen U, Dahlström U, Carstensen J, Rehfeld JF, **Gøtze JP**. Combined measurement of copeptin, high-sensitivity troponin T, and N-terminal proBNP improves the identification of patients at risk of cardiovascular death. *Cardiovasc Endocrinol* 2012;**1**:68-73.
82. Alehagen U, Dahlström U, Rehfeld JF, **Gøtze JP**. Pro-A-type natriuretic peptide, proadrenomedullin, and N-terminal pro-B-type natriuretic peptide used in a multimarker strategy in primary health care in risk assessment of patients with symptoms of heart failure. *J Card Fail* 2013;**19**:31-39.
83. Smith J, Halse KG, Damm P, Lindegaard MLS, Amer-Wählin I, Hertel S, Johansen M, Mathiesen ER, Nielsen LB, **Gøtze JP**. Copeptin and MR-proADM in umbilical cord plasma reflect perinatal stress in neonates born to mothers with diabetes and MR-proANP reflects maternal diabetes. *Biomark Med* 2013;**7**:139-146.
84. Mygind ND, Iversen K, Køber L, **Gøtze JP**, Nielsen H, Boesgaard S, Bay M, Johansen J, Nielsen OW, Kirk V, Kastrup J. The inflammatory biomarker YKL-40 at admission is a strong predictor of overall mortality. *J Intern Med* 2013;**273**:205-216.
85. Iversen K, Køber L, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW. Troponin T is a strong marker of mortality in hospitalized patients. *Int J Cardiol* 2013;**168**:818-824.
86. Harutyunyan M, **Gøtze JP**, Winkel P, Johansen JS, Hansen JF, Jensen GB, Hilden J, Kjølner E, Kolmos HJ, Gluud C, Kastrup J. Serum YKL-40 predicts long-term mortality in patients with stable coronary disease: A prognostic study within the CLARICOR trial. *Immunobiology* 2013;**218**:945-951.
87. **Gøtze JP**, Eiland S, Svendsen LB, Vainer B, Hannibal J, Rehfeld JF. Characterization of gastrins and their receptor in solid human gastric adenocarcinomas. *Scand J Gastroenterol* 2013;**48**:688-695.

88. Smith J, Christoffersen C, Nørgaard LM, Olsen LH, Vejstrup NG, Andersen CB, **Gøtze JP**. Cardiac natriuretic peptide gene expression and plasma concentrations during the first 72 hours of life in pigs. *Endocrinology* 2013;**154**:1864-1872.
89. **Gøtze JP**. Plasma proANP decreases after meal intake. *Clin Chem* 2013;**59**:1270-1271.
90. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, **Gøtze JP**, Esler M, Jeppesen JL. Relative atrial natriuretic peptide deficiency and inadequate renin and angiotensin II suppression in obese hypertensive men. *Hypertension* 2013;**62**:147-153.
91. Halse KG, Lindegaard LS, Amer-Wahlin I, Hertel S, Johansen M, Nielsen LB, **Gøtze JP**, Mathiesen ER, Damm P. Cardiac function in offspring of women with diabetes using fetal ECG, umbilical cord blood pro-BNP, and neonatal interventricular septal thickness. *Cardiovasc Endocrinol* 2013;**2**:55-59.
92. Bonfils PK, Taskiran M, Damgaard M, **Gøtze JP**, Floyd AK, Funch-Jensen P, Kristiansen VB, Gadsbøll N. The influence of high versus low sodium intake on blood pressure and haemodynamics in patients with morbid obesity. *J Hypertens* 2013;**31**:2220-2229.
93. Krogh J, **Gøtze JP**, Jørgensen MB, Kristensen LØ, Kistorp C, Nordentoft M. Copeptin during rest and exercise in major depression. *J Affect Disord* 2013;**151**:284-290.
94. Frydland M, Kousholt B, Larsen JR, Burnett JC Jr, Hilsted L, Hasenkam JM, **Gøtze JP**. Increased N-terminal CgA in circulation associated with cardiac reperfusion in pigs. *Biomark Med* 2013;**7**:959-967.
95. Cirera S, Moesgaard SG, Zois NE, Ravn N, **Gøtze JP**, Cremer SE, Teerlink T, Leifsson PS, Hønge JL, Hasenkam MJ, Olsen LH. Plasma proANP and SDMA and microRNAs are associated with chronic mitral regurgitation in a pig model. *Endocr Connect* 2013;**2**:161-171.
96. Lauridsen BK, Iversen K, Hunter I, Bay M, Kirk V, Nielsen OW, Nielsen H, Boesgaard S, Køber L, **Gøtze JP**. ProANP plasma measurement predicts all-cause mortality in acutely hospitalised patients: a cohort study. *BMJ Open* 2013;**3**:e003288.
97. Christensen HM, Schou M, **Gøtze JP**, Faber J, Frystyk J, Flyvbjerg A, Kistorp C. Body mass index in chronic heart failure: association with biomarkers of neurohormonal activation, inflammation and endothelial dysfunction. *BMC Cardiovasc Disord* 2013;**13**:80.
98. Bosselmann H, Egstrup M, Rossing K, Gustafsson I, Gustafsson F, Tønder N, Kistorp CN, **Gøtze JP**, Schou M. Prognostic significance of cardiovascular biomarkers and renal dysfunction in outpatients with systolic heart failure: A long term follow-up study. *Int J Cardiol* 2013;**170**:202-207.
99. Wiese S, Mortensen C, **Gøtze JP**, Christensen E, Andersen O, Bendtsen F, Møller S. Cardiac and proinflammatory markers predict prognosis in cirrhosis. *Liver Int* 2014;**34**:e19-30.
100. Lyngbæk S, Winkel P, **Gøtze JP**, Kastrup J, Gluud C, Kolmos HJ, Kjølner E, Jensen GB, Hansen JF, Hildebrandt P, Hilden J, the CLARICOR Trial Group. Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide. *Eur J Prev Cardiol* 2014;**21**:1275-1284.
101. Rank UC, Hovinga JK, Taleghani MM, Lämmle B, **Gøtze JP**, Nielsen OJ. Congenital thrombotic thrombocytopenic purpura caused by new compound heterozygous mutations of the *ADAMTS13* gene. *Eur J Haematol* 2014;**92**:168-171.

102. Ruwald MH, **Gøtzte JP**, Bech J, Nielsen OW, Madsen BK, Nielsen LB, Mouridsen M, Ruwald A-CH, Madsen JK, Pedersen S. NT-proBNP independently predicts long-term mortality in patients admitted for coronary angiography. *Angiology*; 2014;**65**:31-36.
103. Asferg C, Nielsen SJ, Andersen UB, Linneberg A, Møller DV, Hedley PL, Christiansen M, **Gøtzte JP**, Jeppesen J. Metabolic rather than body composition measurements are associated with lower serum natriuretic peptide concentrations in normal weight and obese men. *Am J Hypertens* 2014;**27**:620-627.
104. Gustafsson G, Gude E, Sigurdardottir V, Aukrust P, Solbu D, **Gøtzte JP**, Gullestad L. Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels. *Biomark Med* 2014;**8**:239-245.
105. Rehfeld JF, Bardram L, Hilsted L, **Gøtzte JP**. An evaluation of chromogranin A versus gastrin and progastrin in gastrinoma diagnosis and control. *Biomark Med* 2014;**8**:571-580.
106. Hansen LH, Smith J, **Gøtzte JP**. Cardiac C-type natriuretic peptide gene expression and plasma concentrations in neonatal piglets. *Regul Pept* 2014;**188**:66-69.
107. Skov J, Holst JJ, **Gøtzte JP**, Frøkiær J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. *Endocr Connect* 2014;**3**:11-16.
108. Dalsgaard M, Iversen K, Kjaergaard J, Grande P, **Gøtzte JP**, Clemmensen P, Hassager C. Short-term hemodynamic effect of angiotensin-converting enzyme inhibition in patients with severe aortic stenosis. A placebo-controlled, randomized study. *Am Heart J* 2014;**167**:226-234.
109. Kimer N, **Gøtzte JP**, Bendtsen F, Møller S. New vasoactive peptides in cirrhosis: organ extraction and relation to the vasodilatory state. *Eur J Clin Invest* 2014;**44**:441-452.
110. **Gøtzte JP**, Hilsted L, Rehfeld JF, Alehagen U. Plasma chromogranin A is a marker of death in elderly patients presenting with symptoms of heart failure. *Endocr Connect* 2014;**3**:47-56.
111. Asferg CL, Andersen UB, Linneberg A, **Gøtzte JP**, Jeppesen JL. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher glucose and insulin concentrations but not higher blood pressure in obese men. *Diabet Med* 2014;**31**:728-732.
112. Bosselmann H, Tonder N, Sölétormos G, Rossing K, Iversen K, **Gøtzte JP**, Gustafsson F, Schou M. Influence of renal impairment on myocardial function in outpatients with systolic heart failure: an echocardiographic and cardiac biomarker study. *Int J Cardiol* 2014;**177**:942-948.
113. Timm A, Fahrenkrug J, Jørgensen HL, Sennels HP, **Gøtzte JP**. Diurnal variation of von Willebrand factor in plasma: the Bispebjerg study of diurnal variations. *Eur J Haematol* 2014;**93**:48-53.
114. Christensen DL, Espino D, Infante-Ramírez R, Brage S, Terzic D, **Gøtzte JP**, Kjaergaard J. Normalization of elevated cardiac, kidney, and hemolysis plasma markers within 48 h in Mexican Tarahumara runners following a 78 km race at moderate altitude. *Am J Hum Biol* 2014;**26**:836-43.
115. Kistorp C, Bliddal H, **Gøtzte JP**, Christensen R, Faber J. Cardiac natriuretic peptides in plasma increase after dietary induced weight loss in obesity. *BMC Obesity* 2014;**1**:24. Online publication.

116. Iversen K, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW, Køber LV. Risk stratification in emergency patients by copeptin. *BMC Medicine* 2014;**12**:80.
117. Andersen MJ, Ersbøll M, Bro-Jeppesen J, Møller JE, Hassager C, Køber L, Borlaug BA, **Gøtze JP**, Gustafsson F. Relationships between biomarkers and left ventricular filling pressures at rest and during exercise in patients after myocardial infarction. *J Cardiac Failure* 2014;**20**:959-67.
118. Balling L, Gustafsson F, **Gøtze JP**, Dalsgaard M, Nielsen H, Boesgaard S, Bay M, Kirk V, Nielsen OW, Køber L, Iversen K. Hyponatremia at hospital admission is a predictor of overall mortality. *J Intern Med* 2015;**45**:195-202.
119. Timm A, Hillarp A, Philips M, **Gøtze JP**. Comparison of automated von Willebrand factor activity assays. *Thrombosis Res* 2015;**135**:684-691.
120. Lippert SK, Iversen P, Brasso K, **Gøtze JP**. C-type natriuretic peptide and its precursor: Potential markers in human prostate cancer. *Biomark Med* 2015;**9**:319-326.
121. **Gøtze JP**, Johnsen AH, Johnbeck CB, Rehfeld JF. Cardiomyocyte expression and cell-specific processing of procholecystokinin. *J Biol Chem* 2015;**290**:6837-6843.
122. Holmager P, Schou M, Egstrup M, Gustafsson I, **Gøtze JP**, Gustafsson F, Klausen TW, Faber J, Kistorp K. The influence of diabetes mellitus on mid-regional pro-adrenomedullin concentrations and prognostic value in heart failure patients. *J Cardiac Failure* 2015;**21**:250-257.
123. Joergensen C, Tarnow L, **Gøtze JP**, Rossing P. Vitamin D analogue therapy, cardiovascular risk and kidney function in type 1 diabetic patients with diabetic nephropathy – a randomized trial. *Diabetic Med* 2015;**32**:343-352.
124. Kjeld T, Jattu T, Nielsen HB, **Gøtze JP**, Secher NH, Olsen NV. Release of EPO, S100B and neuron-specific enolase after breath-hold in free divers. *Scand J Med Sci Sports* 2015;**25**:253-257.
125. Lindberg S, Jensen JS, Pedersen SH, Galatius S, **Gøtze JP**, Møgelvang R. MR-ProANP improves prediction of mortality and cardiovascular events in patients with STEMI. *Eur J Prev Cardiol* 2015;**22**:693-700.
126. Bonfils PK, Taskiran M, Damgaard M, **Gøtze JP**, Floyd AK, Funch-Jensen P, Kristiansen VB, Støckel M, Bouchelouche PN, Gadsbøll N. Roux-en-Y gastric bypass alleviates hypertension and is associated with an increase in mid-regional pro-atrial natriuretic peptide in morbid obese patients. *J Hypertens* 2015;**33**:1215-1225.
127. Von Scholten BJ, Lajer M, **Gøtze JP**, Persson F, Rossing P. Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment. *Diabet Med* 2015;**32**:343-352.
128. Theilade S, Hansen TW, **Gøtze JP**, Rossing P. Increased Plasma concentrations of midregional proatrial natriuretic peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes. *Am J Hypertens* 2015;**28**:772-779.
129. Von Scholten BJ, Hansen TW, **Gøtze JP**, Persson F, Rossing P. Glucagon-like peptide 1 receptor antagonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes. *J Diabetes Complications* 2015;**29**:670-674.

130. Schou M, Bosselmann H, Gaborit F, Iversen K, **Gøtzte JP**, Sölétormos G, Rasmussen J, Kistorp C, Kober L, Gustafsson F, Tonder N. Iron Deficiency: Prevalence and relation to cardiovascular biomarkers in heart failure outpatients. *Int J Cardiol* 2015;**195**:143-148.
131. Mylin AK, **Gøtzte JP**, Heickendorff L, Ahlberg L, Dahl IM, Abildgaard N, Gimsing P. N-terminal pro-C-type natriuretic peptide in serum associated with bone destruction in patients with multiple myeloma. *Biomark Med* 2015;**9**:679-689.
132. Smith J, Fahrenkrug J, Jørgensen HL, Christoffersen C, **Gøtzte JP**. Diurnal gene expression of lipolytic natriuretic peptide receptors in white adipose tissue. *Endocr Connect* 2015;**4**:206-214.
133. Siebenmann C, Cathomen A, Hug M, Keiser S, Lundby AK, Hilty MP, **Gøtzte JP**, Rasmussen P, Lundby C. Hemoglobin mass and intravascular volume kinetics during and after exposure to 3,454-m altitude. *J Appl Physiol* 2015;**119**:1194-1201.
134. Goharian TS, Gimsing AN, **Gøtzte JP**, Faber J, Andersen LB, Grøntved A, Jeppesen JL. Mid-regional pro-atrial natriuretic peptide and blood pressure in adolescents: Effect of gender and pubertal stage. *Blood Press* 2015;**24**:347-352.
135. Gaborit F, Bosselmann H, Tønder N, Iversen K, Kümler T, Kistorp C, Sölétormos G, **Gøtzte JP**, Schou M. Association between left ventricular global longitudinal strain and natriuretic peptides in outpatients with chronic systolic heart failure. *BMC Cardiovasc Disord* 2015;**15**:92. doi:10.1186/s12872-015-0063-8.
136. Lindberg S, Jensen JS, Hoffmann S, Pedersen SH, Iversen AZ, Galatius S, Frystyk J, Flyvbjerg A, **Gøtzte JP**, Bjerre M, Mogelvang R. Interplay between adiponectin, pro-atrial natriuretic peptide and prognosis in patients with ST-Segment Elevation Myocardial Infarction. *Am J Cardiol* 2015;**116**:1340-1345.
137. Guo S, **Gøtzte JP**, Jeppesen JL, Burnett Jr JC, Olesen J, Jansen-Olesen I, Ashina M. Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers. *Peptides* 2015;**74**:33-42.
138. Fabiansen C, Lykke M, Hother A-L, Koch J, Nielsen OB, Hunter I, **Gøtzte JP**, Friis H, Thymann T. Cardiac dysfunction in a porcine model of pediatric malnutrition. *PLoS One* 2015;**10**:e0140472 (1-16).
139. Van Der Vekens N, Hunter I, Timm A, Decloedt A, De Clercq D, Deprez P, **Gøtzte JP**, van Loon G. Total plasma proANP increases atrial dilatation in horses. *Vet Rec* 2015;**177**:624. doi: 10.1136/vr.103316.
140. Wiese S, Timm A, Nielsen LB, **Gøtzte JP**, Bendtsen F, Møller S. Plasma ADAMTS-13 protein is not associated with portal hypertension or hemodynamic changes in patients with cirrhosis. *Dig Liver Dis* 2016;**48**:404-408.
141. Rasmussen KC, Højskov M, Ruhnau B, Salling L, Pedersen T, **Gøtzte JP**, Secher NH. Plasma pro-atrial natriuretic peptide to indicate fluid balance during cystectomy: a prospective observational study. *BMJ Open* 2016;**6**:e010323.
142. Skov J, Pedersen M, Holst JJ, Madsen B, **Gøtzte JP**, Rittig S, Jonassen T, Frøkiær J, Dejgaard A, Christiansen JS. Short-term effects of liraglutide on kidney function and vasoactive hormones in type 2 diabetes: a randomized clinical trial. *Diabetes Obes Metab* 2016;**18**:581-589.
143. **Gøtzte JP**, Rehfeld JF, Alehagen U. Cholecystokinin in plasma predicts cardiovascular mortality in elderly females. *Int J Cardiol* 2016;**209**:37-41.

144. Gaborit FS, Bosselmann H, Kistorp C, Iversen K, Kumler T, Gustafsson F, **Gøtze JP**, Sölétormos G, Tønder N, Schou M. Galectin 3: association to neurohumoral activity, echocardiographic parameters and renal function in outpatients with heart failure. *BMC Cardiovasc Disord* 2016;**16**:117.
145. Montero D, Rauber S, **Gøtze JP**, Lundby C. Reduction in central venous pressure enhances erythropoietin synthesis: role of volume-regulating hormones. *Acta Physiol* 2016;**218**:89-97.
146. Vedel AG, Holmgaard F, Rasmussen LS, Paulson OB, Thomsen C, Danielsen ER, Langkilde A, **Gøtze JP**, Lange T, Ravn HB, Nilsson JC. Perfusion Pressure Cerebral Infarct (PPCI) trial - the importance of mean arterial pressure during cardiopulmonary bypass to prevent cerebral complications after cardiac surgery: study protocol for a randomised controlled trial. *Trials* 2016;**17**:247.
147. Jung MH, **Gøtze JP**, Boesgaard S, Sander K, Gustafsson F. Neurohormonal activation and exercise tolerance in patients supported with a continuous-flow left ventricular assist device. *Int J Cardiol* 2016;**220**:196-200.
148. Ghulam QM, Bredahl KK, Gram JB, Löhn L, **Gøtze JP**, Sillesen HH, Eiberg J. Von Willebrand factor and prekallikrein in plasma are associated with thrombus volume in abdominal aortic aneurysms. *Vasc Endovascular Surg* 2016;**50**:391-397.
149. Vestergaard KR, Jespersen CB, Arnadottir A, Sölétormos G, Schou M, Steffensen R, **Gøtze JP**, Kjølner E, Iversen KK. Prevalence and significance of troponin elevations in patients without acute coronary disease. *Int J Cardiol* 2016;**222**:819-825.
150. Asferg CL, Andersen UB, Linneberg A, Hedley PL, Christiansen M, **Gøtze JP**, Jeppesen JL. Serum proatrial natriuretic peptide does not increase with higher systolic blood pressure in obese men. *Heart* 2017;**103**:154-158.
151. Plesner LL, Schoos MM, Dalsgaard M, **Gøtze JP**, Kjølner E, Vestbo J, Iversen K. Iron deficiency in COPD associates with increased pulmonary artery pressure estimated by Echocardiography. *Heart Lung Circ* 2017;**26**:101-104.
152. Saenger AK, Rodriguez-Fraga O, Ler R, Ordonez-Llanos J, Jaffe AS, **Gøtze JP**, Apple FS. Specificity of B-type natriuretic peptide assays: cross-reactivity with different BNP, NT-proBNP, and proBNP peptides. *Clin Chem* 2017;**63**:351-358.
153. Strandby RB, Ambrus R, Secher NH, **Gøtze JP**, Achiam MP, Svendsen LB. Plasma pro-atrial natriuretic peptide to estimate fluid balance during open and robot-assisted esophagectomy: a prospective observational study. *BMC Anesthesiol* 2017;**17**:20.
154. Sørensen H, Thomsen JH, Meyer ASP, Terzic D, Hilsted L, Kjærgaard J, **Gøtze JP**, Barbosa TC, Secher NH. Phenylephrine increases near-infrared spectroscopy determined muscle oxygenation in men. *J Clin Monit Comput* 2017;**31**:1159-1166.
155. Ambrus R, Svendsen LB, Secher NH, **Gøtze JP**, Rünitz K, Achiam MP. Severe postoperative complications may be related to mesenteric traction syndrome during open esophagectomy. *Scand J Surg* 2017;**106**:241-248.
156. Bejder J, Andersen AB, **Gøtze JP**, Aachmann-Andersen NJ, Nordsborg NB. Plasma volume reduction and hematological fluctuations in high-level athletes after an increased training load. *Scand J Med Sci Sports* 2017;**27**:1605-1615.
157. Sonne DP, Terzic D, Knop FK, **Gøtze JP**. Postprandial plasma concentrations of proANP in patients with type 2 diabetes and healthy controls. *Clin Chem* 2017;**63**:1040-1041.

158. **Gøtze JP**, Hansen CP, Rehfeld JF. Acute effects of N-terminal progastrin fragments on gastric acid secretion in man. *Physiol Rep* 2017;**5**:e13164.
159. Goharian TS, **Gøtze JP**, Faber J, Andersen LB, Grøntved A, Jeppesen JL. Associations of proatrial natriuretic peptide with components of the metabolic syndrome in adolescents and young adults from the general population. *Am J Hypertens* 2017;**30**:561-568.
160. Zois NE, Terzic D, Færch K, Plomgaard P, Hansen JS, Rossing P, **Gøtze JP**. Effect of pancreatic hormones on pro-atrial natriuretic peptide in humans. *EBioMedicine* 2017;**17**:88-94.
161. Montero D, Breenfeldt-Andersen A, Oberholzer L, Haider T, **Gøtze JP**, Meinild-Lundby A-K, Lundby C. Erythropoiesis with endurance training: dynamics and mechanisms. *Am J Physiol Regul Integr Comp Physiol* 2017;**312**:R894-R902.
162. Hansen LH, Darkner S, Svendsen JH, Henningsen K, Pehrson S, Chen X, Vakhrushev SY, Schjoldager KT, **Gøtze JP**. Chromogranin A in the mammalian heart: expression without secretion. *Biomark Med* 2017;**11**:541-545.
163. Hagdrup C, Park-Hansen J, Svendsen JH, **Gøtze JP**, Holme S, Carranza CL, Nilsson B, Steinbrüchel D, Irmukhamedov A, Dominguez H. Mr-proanp rises during exercise even after surgical closure of the left atrial appendage: a sub-study of the Laacs randomized study. *J Cardio Vasc Med* 2017;**3**:102.
164. Darkner S, **Gøtze JP**, Chen X, Henningsen K, Pehrson S, Svendsen JH. Natriuretic propeptides as markers of atrial fibrillation burden and recurrence (from the AMIO-CAT trial). *Am J Cardiol* 2017;**120**:1309-1315.
165. Jensen KOF, Hansen SH, **Gøtze JP**, Jesting A, Stensballe J, Hansen H. Preliminary report: Measurement of apixapan and rivaroxapan in plasma from bleeding patients. *Eur J Haematol* 2017;**99**:431-436.
166. Bosselmann H, Tonder N, Sölétormos G, Gaborit F, Rossing K, Iversen K, **Gøtze JP**, Gustafsson F, Schou M. Influence of renal impairment on aldosterone status, calcium metabolism, and vasopressin activity in outpatients with systolic heart failure. *ESC Heart Failure* 2017;**4**:554-562.
167. Christensen DL, Espino D, Infante-Ramirez R, Cervantes-Borunda MS, Hernandez-Torres RP, Rivera-Cisneros AE, Castillo D, Westgate K, Terzic D, Brage S, Hassager C, **Gøtze JP**, Kjaergaard J. Transient cardiac dysfunction but elevated cardiac and kidney biomarkers 24 h following an ultra-distance running event in Mexican Tarahumara. *Extrem Physiol Med* 2017;**6**:3.
168. Mark PD, Hunter I, Terzic D, **Gøtze JP**. Processing-independent proANP measurement for low concentrations in plasma: reference intervals and effect of body mass index and plasma glucose. *Clin Chem Lab Med*, 2018;**56**:132-137.
169. Busk TM, Bendtsen F, Poulsen JH, Clemmesen JO, Larsen FS, **Gøtze JP**, Iversen JS, Jensen MT, Møgelvang R, Pedersen EB, Bech JN, Møller S. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis. *Am J Physiol Gastrointest Liver Physiol* 2018;**314**:G275-G286.
170. Arnadottir A, Vestergaard KR, Pallisgaard J, Soletormos G, Steffensen R, **Gøtze JP**, Iversen K. High-sensitivity cardiac troponin T is superior to troponin I in the prediction of mortality in patients without acute coronary syndrome. *Int J Cardiol* 2018;**259**:186-191.

171. Asferg CL, Andersen UB, Linneberg A, **Gøtze JP**, Jeppesen JL. Obese hypertensive men have lower circulating proatrial natriuretic peptide concentrations despite greater left atrial size. *Am J Hypertens* 2018;**31**:645-650.
172. Asferg CL, Nielsen SJ, Andersen UB, Linneberg A, **Gøtze JP**, Jeppesen J. Serum proatrial natriuretic peptide concentrations during oral glucose-induced acute hyperinsulinemia in lean and obese men. *Peptides* 2018, in press.
173. Balling L, **Gøtze JP**, Jung MH, Rossing K, Boesgaard S, Gustafsson F. Copeptin levels and invasive hemodynamics in patients with advanced heart failure. *Biomark Med* 2018;**12**:861-870.
174. Wiese S, Hove J, Mo S, Mookerjee RP, Petersen CL, Vester-Andersen MK, Mygind ND, **Gøtze JP**, Kjær A, Bendtsen F, Møller S. Myocardial extracellular volume quantified by magnetic resonance is increased in cirrhosis and related to poor outcome. *Liver Int* 2018;**38**:1614-1623.
175. Rasmussen T, Follin B, Kastrup J, Brandt-Larsen M, Madsen J, Christensen TE, Juhl M, Cohen S, Hammelev KP, Møller CJH, **Gøtze JP**, Hasbak P, Kjær A. Angiogenesis PET tracer uptake (^{68}Ga -NODAGA-E[(cRGDyK)]₂) in induced myocardial infarction and stromal cell treatment in minipigs. *Diagnostics (Basel)* 2018;**8**:33.
176. Falkentoft AC, Rørth R, Iversen K, Høfsten DE, Kelbæk H, Holmvang L, Frydland M, Schoos MM, Helqvist S, Axelsson A, Clemmensen P, Jørgensen E, Saunamäki K, Tilsted HH, Pedersen F, Torp-Pedersen C, Kofoed KF, **Gøtze JP**, Engstrøm T, Køber L. MR-proADM as a prognostic marker in patients with ST-segment-elevation myocardial infarction—DANAMI-3 (a Danish study of optimal acute treatment of patients with STEMI) substudy. *J Am Heart Assoc* 2018;**18**:7.
177. Frydland M, Møller JE, Wiberg S, Lindholm MG, Hansen R, Henriques JS, Helgestad-Møller OK, Bang LE, **Gøtze JP**, Thomsen JH, Ouweneel, Obling L, Ravn HB, Holmvang L, Jensen LO, Kjærgaard J, Hassager C. Lactic acid measurement adds prognostic information on 30-day mortality to variables defining cardiogenic shock in patients presenting with STEMI. *Shock*, in press.
178. De Neergaard R, Nielsen JE, Jørgensen A, Toft BG, **Gøtze JP**, Jørgensen N. Positive association between cholesterol in human seminal plasma and sperm counts: results from a cross-sectional cohort study and immunohistochemical investigations. *Andrology*, in press.
179. Árnadóttir A, Vestergaard KR, Sölétormos G, Steffensen R, **Gøtze JP**, Iversen K. Prediction of coronary heart disease or heart failure using high-sensitivity cardiac troponin T: A pilot study. *Eur J Clin Invest* 2018;**48**:e13009.
180. **Gøtze JP**, Hunter I, Zois NE, Terzic D, Valeur N, Olsen LH, Smith J, Plomgaard P, Hansen LH, Rehfeld JF, Balling L, Gustafsson F. Cardiac procholecystokinin expression during hemodynamic changes in the mammalian heart. *Peptides* 2018;**108**:7-13.
181. Asferg CL, Andersen UB, Linneberg A, **Gøtze JP**, Holst JJ, Jeppesen J. Copeptin, a surrogate marker for arginine vasopressin secretion, is associated with higher plasma glucagon. *Diabetic Med*, in press.
182. Hejl JL, Grand MK, Siersma V, **Gøtze JP**, Olivarius NdF, Andersen CL, Lind B. Brian natriuretic peptide in plasma as predictor of all-cause mortality in a large Danish primary health care population suspected of heart failure. *Clin Chem* 2018;**64**:1723-1731.

183. **Gøtze JP**, Gustafsson F, Borby O, Støvring RK. MR-proANP associated with body mass index in patients with anorexia nervosa in the absence of heart failure. *J Appl Lab Med*, in press.
184. Ring LL, Strandby RB, Henriksen A, Ambrus R, Sørensen H, **Gøtze JP**, Svendsen LB, Achiam MP. Laser speckle contrast imaging for quantitative assessment of facial flushing during mesenteric traction syndrome in upper gastrointestinal surgery. *J Clin Monit Comput*, in press.
185. Bartels ED, Guo S, Kousholt BS, Larsen JR, Hasenkam M, Burnett Jr JC, Nielsen LB, Ashima M, **Gøtze JP**. High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs. *Peptides* 2019;**112**:43-47.

II. Oversigtsartikler & letters (42)

1. Rehfeld JF, Bardram L, Bundgaard JR, Friis-Hansen L, **Gøtze JP**, Hilsted L, Johnsen AH, Lüttichau HR, Nielsen FC, Paloheimo L, Pedersen K, Rourke IJ, van Solinge WW, Thorup JU. Expression and growth effects of gastrin and cholecystokinin peptides in neuroendocrine tumors and common carcinomas. *Falk Symposium No. 77: Gastrointestinal tract and endocrine system* (Klüwer Academic Publications, Lancaster, UK, 1995; pp. 379-405).
2. **Gøtze JP**, Kastrup J. Plasma pro-brain natriuretic peptides are strong biochemical markers in clinical cardiology. *Scand J Clin Lab Invest Suppl* 2001;**234**:47-51.
3. Rehfeld JF, **Gøtze JP**. The posttranslational phase of gene expression: new possibilities in molecular diagnosis. *Curr Mol Med* 2003;**3**:25-38.
4. Rehfeld JF, Bundgaard JR, **Gøtze JP**, Friis-Hansen L, Hilsted L, Johnsen AH. Progastrin, gastrins and bioactivity. Proceedings of the 11th International Conference on Ulcer Research, Dubrovnik, Croatia, September 15-20, 2003.
5. Rehfeld JF, Bundgaard JR, Friis-Hansen L, **Gøtze JP**. On the tissue-specific processing of procholecystokinin in the brain and gut – a short review. *J Physiol Pharmacol* 2003;**54** Suppl 4:73-79.
6. Nielsen SJ, **Gøtze JP**, Raymond IE, Grønning BA, Kirk V, Bay M, Hildebrandt PR, Aldershvile J. De natriuretiske hjertehormoner. Klinisk anvendelse ved hjertesvigt. *Ugeskr Laeger* 2004;**166**:248-253.
7. Rehfeld JF, Bundgaard JR, **Gøtze JP**, Friis-Hansen L, Hilsted L, Johnsen AH. Naming progastrin-derived peptides. *Regul Pept* 2004;**120**:177-183.
8. **Gøtze JP**. ProBNP-derived peptides in cardiac disease. *Scand J Clin Lab Invest* 2004;**64**:497-510.
9. **Gøtze JP**. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. *Clin Chem* 2004;**50**:1503-1510.
10. Friis-Hansen L, **Gøtze JP**, Kastrup J. Forgiftning med betablokkere og calciumantagonister. To kardiologiske problemer med endokrinologiske løsninger? *Ugeskr Laeger* 2004;**166**:3483-3487.
11. **Gøtze JP**, Rehfeld JF. Cardiac processing of natriuretic peptides in heart failure. *Clin Chem* 2004;**50**:2467-2468.
12. Nielsen LB, **Gøtze JP**. Letter regarding article by Bibbins-Domingo et al, "B-type natriuretic peptide and ischemia in patients with stable coronary disease: data from the Heart and Soul study". (Measurement of BNP versus proBNP in patients with coronary artery disease.) *Circulation* 2005;**111**:15-16.
13. Rehfeld JF, **Gøtze JP**. Gastrin vaccination against gastrointestinal and pancreatic cancer. *Scand J Gastroenterol* 2006;**41**:122-123.
14. **Gøtze JP**, Friis-Hansen L, Rehfeld JF, Nilsson B, Svendsen JH. Atrial secretion of B-type natriuretic peptide. *Eur Heart J* 2006;**27**:1648-1650.
15. Rehfeld JF, Friis-Hansen L, **Gøtze JP**, Hansen TvO. The biology of cholecystokinin and gastrin peptides. *Curr Top Med Chem* 2007;**7**:1154-1165.

16. **Gøtze JP**, Hillarp A, Lindblom A, Björk P, Strandberg K, Nielsen LB. Ny markør ved trombotisk trombocytopenisk purpura. *Ugeskr Laeger* 2008;**170**:2446-2449.
17. **Gøtze JP**, Lindblom A, Björk P, Nielsen LB, Strandberg K, Manea M, Hillarp A. ADAMTS13 – aktör och markör vid trombotisk mikroangiopati. *Läkartidningen* 2008;**105**:1092-1095.
18. Christoffersen C, Lethagen S, **Gøtze JP**. Heparininduceret trombocytopeni. *Ugeskr Laeger* 2009;**171**:612-615.
19. Smith J, **Gøtze JP**, Andersen CB, Vejlstrup N. Practical application of natriuretic peptides in paediatric cardiology. *Cardiol Young* 2010;**20**:353-363.
20. Veien KT, Jensen JK, Hildebrandt P, **Gøtze JP**, Nielsen OW, Køber L. Natriuretiske peptider som hjertemarkører i klinisk praksis. *Ugeskr Laeger* 2010;**172**:2111-2116.
21. Lippert SK, **Gøtze JP**. C-type natriuretic-derived peptides as biomarkers in human disease. *Biomark Med* 2010;**4**:631-639.
22. **Gøtze JP**, Johnsen AH, Rehfeld JF. Letter regarding article by Siriwardena M et al.: B-type natriuretic peptide signal peptide circulates in human blood: evaluation as a potential biomarker of cardiac ischemia. *Circulation* 2011;**123**:e232.
23. Rehfeld JF, Friis-Hansen L, **Gøtze JP**, Hilsted L, Nielsen FC. Diagnostik af neuroendokrine tumorer i mave-tarm-kanalen. *Ugeskr Laeger* 2010;**172**:2957-2960.
24. Crimmins DL, **Gøtze JP**. In vitro molecular structure of N-terminal B-type natriuretic peptide: monomer or oligomer? *Clin Chem* 2011;**57**:924-926.
25. **Gøtze JP**, Hunter I, Lippert SK, Bardram L, Rehfeld JF. Processing-independent analysis of peptide hormones and prohormones in plasma. *Front Biosci (Landmark Ed.)* 2012;**17**:1804-1815.
26. **Gøtze JP**. B-type natriuretic peptide: From post-translational processing to clinical measurement. *Clin Chem* 2012;**58**:83-91.
27. Rehfeld JF, Bardram L, Hilsted L, Poitras P, **Gøtze JP**. Pitfalls in diagnostic gastrin measurements. *Clin Chem* 2012;**58**:831-836.
28. **Gøtze JP**, Hunter I, Smith J, Hasenkam JM. Pigs in space. *Cardiovasc Endocrinol* 2013;**2**:4-5.
29. **Gøtze JP**, Alehagen U, Flyvbjerg A, Rehfeld JF. Making sense of chromogranin A in heart disease. *Lancet Diabetes Endocrinol* 2013;**1**:7-8.
30. Bergen M, **Gøtze JP**. On the nature of depression: cardiovascular light for a shady condition. *Cardiovasc Endocrinol* 2013;**2**:38-39.
31. Van Der Vekens N, Hunter I, **Gøtze JP**, Decloedt A, De Clercq D, Van Loon G. Human and equine cardiovascular endocrinology: beware to compare. *Cardiovasc Endocrinol* 2013;**2**:67-76.
32. **Gøtze JP**, Alehagen U, Flyvbjerg A, Rehfeld JF. Chromogranin A as a biomarker in cardiovascular disease. *Biomark Med* 2014;**8**:133-140.
33. Hunter I, Terzic D, Zois NE, Olsen LH, **Gøtze JP**. Pig models for the human heart failure syndrome. *Cardiovasc Endocrinol* 2014;**3**:15-18.

34. Okholm C, **Gøtze JP**, Svendsen LB, Achiam MP. Inflammatory response in laparoscopic vs. open surgery for gastric cancer. *Scand J Gastroenterol* 2014;**49**:1027-1034.
35. Zois NE, Bartels ED, Hunter I, Kousholt BS, Olsen LH, **Gøtze JP**. Natriuretic peptides in cardiometabolic regulation and disease. *Nat Rev Cardiol* 2014;**11**:403-412.
36. Jespersen CHB, Vestergaard KR, Schou M, Teisner B, **Gøtze JP**, Iversen K. Pregnancy-associated plasma protein-A and the vulnerable plaque. *Biomark Med* 2014;**8**:1033-1047.
37. Guo S, Barringer F, Zois NE, **Gøtze JP**, Ashina M. Natriuretic peptides and cerebral hemodynamics. *Regul Pept* 2014;**193**:15-23.
38. Albrethsen J, **Gøtze JP**, Johnsen AH. Mining the granule proteome: a potential source of endocrine biomarkers. *Biomark Med* 2015;**9**:259-265.
39. **Gøtze JP**, Hansen LH, Terzic D, Zois NE, Albrethsen J, Timm A, Smith J, Soltysinska E, Lippert SK, Hunter I. Atrial natriuretic peptides in plasma. *Clin Chim Acta* 2015;**443**:25-28.
40. **Gøtze JP**, Rehfeld JF. Scientists Should Be Writing: Three reasons why authorship matters, even—perhaps especially—to established scholars. *The Scientist*, online publication, April 7, 2015.
41. Rehfeld JF, Hansen JS, Sonne DP, **Gøtze JP**. Biomarkers and immunoassay kits: a matter of growing concern. *Biomark Med* 2015;**9**:623-624.
42. **Gøtze JP**, Rehfeld JF. Procholecystokinin expression and processing in cardiac myocytes. *Peptides*, in press.

III. Editorials (16)

1. **Gøtzte JP**, Kastrup J, Rehfeld JF. The paradox of increased natriuretic hormones in congestive heart failure patients: Does the endocrine heart also fail in heart failure? *Eur Heart J* 2003;**24**:1471-1472.
2. **Gøtzte JP**, Videbæk R. More hormones spilt in heart failure: linking renal sympathetic activation to clinical outcome. *Eur Heart J* 2005;**26**:861-862.
3. **Gøtzte JP**. Coronary artery disease, heart failure, and cardiac natriuretic peptides in the middle. *Eur Heart J* 2005;**26**:2603-2604.
4. Christoffersen C, Hunter I, Jensen AL, **Gøtzte JP**. Diabetes and the endocrine heart. *Eur Heart J* 2007;**28**:2427-2429.
5. **Gøtzte JP**. Markers of activated coagulation in acute coronary syndromes. *J Am Coll Cardiol* 2008;**51**:2430-2431.
6. **Gøtzte JP**, Rehfeld JF. Peptide hormones and their prohormones as biomarkers. *Biomark Med* 2009;**3**:335-338.
7. Hunter I, **Gøtzte JP**. Next generation natriuretic peptide measurement. *Adv Clin Chem* 2012;**58**:45-48.
8. **Gøtzte JP**. Defining cardiovascular endocrinology. *Cardiovasc Endocrinol* 2012;**1**:2-3.
9. **Gøtzte JP**, Køber L. Genotype versus phenotype in cardiology: just a new coat of paint? *Biomarkers Med* 2013;**7**:501-503.
10. **Gøtzte JP**, Krentz A. Animal models. *Cardiovasc Endocrinol* 2014;**3**:1.
11. **Gøtzte JP**, Albrethsen J. Adropin: A new regulatory peptide in cardiovascular endocrinology. *Regul Pept* 2014;**190-191**:41-42.
12. **Gøtzte JP**, Rehfeld JF. The men who stare at science. *Cardiovasc Endocrinol* 2015;**4**:117-118.
13. **Gøtzte JP**, Rehfeld JF. Antibodies make analyses make answers. *Biomark Med* 2016;**10**:447.
14. **Gøtzte JP**, Zois NE. Cardiac natriuretic peptides in plasma: from prediction to precision medicine. *Lancet Diabetes Endocrinol* 2016;**4**:803-805.
15. **Gøtzte JP**, Sonne DP. Diabetes and its lack of causal biomarkers. *Biomark Med* 2016;**10**:1121-1123.
16. **Gøtzte JP**, Hansen LH, Terzic D, Mark PM, Albrethsen NJW, Plomgaard P, Rehfeld JF. Commentary: measurement of biomarkers in medicine, *Biomark Med* 2018;**12**:941-944.

IV. Bogkapitler (9)

1. Rehfeld JF, **Gøtze JP**. The post-translational phase of gene expression in tumor diagnosis. M.A. Hayat (Ed): Handbook of immunohistochemistry and *in situ* hybridization of human carcinomas (volume 4). *Elsevier Academic Press USA* 2006:23-32.
2. **Gøtze JP**. Biosynthesis of cardiac natriuretic peptides. D. Richter & H. Tiedge (Eds): Cellular Peptide Hormone Synthesis and Secretory Pathways. *Results Probl Cell Differ* 2010;**50**:97-120 (*Springer Press*).
3. Rehfeld JF, **Gøtze JP**. Gastrin. Handbook of Biologically Active Peptides (2nd edition). Kastin AJ (Ed), *Academic Press* 2013:519-523.
4. Apple FS, **Gøtze JP**, Jaffe AS. Cardiac function. Tietz textbook of clinical chemistry and molecular diagnosis (5th edition). *Elsevier Saunders* 2012:1457-1522.
5. Apple FS, **Gøtze JP**, Jaffe AS. Cardiovascular disease. Tietz Fundamentals of Clinical Chemistry and Molecular Diagnostics (7th edition). *Elsevier Saunders* 2014:632-650.
6. Terzic D, **Gøtze JP**. Copeptin and the heart failure syndrome. *UNI-MED Verlag AG* 2014;62-69.
7. Rehfeld JF, **Gøtze JP**. Forskning på Klinisk Biokemisk Afdeling, Rigshospitalet 1954-2014 (ISBN 978-87-990619-1-4).
8. Apple FS, **Gøtze JP**, Jaffe AS. Cardiac function. Tietz textbook of Clinical Chemistry and Molecular Diagnostics (6th edition). *Elsevier, Inc.* 2017:1201-1255.
9. De Bold AJ, Burnett Jr JC, **Gøtze JP**. The endocrine Heart, *in* A Belfiore & D LeRoith (Eds.) *Principles of endocrinology and hormone action*, Springer Publishers (Heidelberg, London, New York) 2018; pp. 533-558.

V. Andre publikationer (20)

1. Friis-Hansen L, **Gøtze JP**, Philip J. Graviditetskomplikationer og trombofili. *Ugeskr Laeger* 1999;**161**:5034.
2. Rehfeld JF, **Gøtze JP**. Barretts metaplasi og øsofaguskræft. *Ugeskr Laeger* 2003;**165**:2498.
3. **Gøtze JP**, Friis-Hansen L, Thorsen S, Rehfeld JF. Langtidsprofylakse efter venøs tromboembolisk sygdom. *Ugeskr Laeger* 2003;**165**:2896-2897.
4. **Gøtze JP**, Rehfeld JF. Hjerterpeptider – basalt set. *Ugeskr Laeger* 2003;**165**:3324-3325.
5. **Gøtze JP**, Rehfeld JF. Hjertehormonologi. *Ugeskr Laeger* 2004;**166**:1109.
6. **Gøtze JP**. Hjertets egne hormoner. *Klinisk Biokemi i Norden* 2005;**17**:8-12.
7. Rehfeld JF, **Gøtze JP**. Galdesten som symptom på kolecystokininresistens. *Ugeskr Laeger* 2005;**167**:2658-2659.
8. **Gøtze JP**, Hansen SH, Johnsen AH. Tacrolimus i blod: Immunsuppressiva analyseret med LC-MS/MS. *DSKB-Nyt* 2006;**2**:26-27.
9. **Gøtze JP**, Svensson PJ. Trombosbehandlingens længde bør ikke styras af D-dimer. *Läkartidningen* 2007;**104**:851.
10. **Gøtze JP**, Nielsen LB. Heparin-induceret immunbetinget trombocytopeni. *DSTH-Forum* 2007;**2**:16-17.
11. **Gøtze JP**, Carlsson M, Friis-Hansen L, Nybo M, Thornemo M, Karlman M, Karawajczyk M, Zelvute I, Janukonyte J, Hel M, Frøyskov B, Aldrimer M. The professional role in a clinical chemistry laboratory: Snapshots from a boat trip to Bornholm. *Klinisk Biokemi i Norden* 2007;**19**:22-31.
12. Hunter I, Jensen AL, Koch J, Bjørnvad C, Smith J, **Gøtze JP**. Det endokrine hjerte og biokemisk diagnostik af hjertesygdom. *Dansk Veterinærtidsskrift* 2008;**91**:8-12.
13. Rehfeld JF, Bardram L, **Gøtze JP**, Hilsted L. Gastrin som markør af gastrinomer: Et lærestykke om immunanalyse-kits. *Klinisk Biokemi i Norden* 2011;**3**:20-24.
14. Hammarsten O, **Gøtze JP**. Copeptin: A new peptide in clinical measurement. *Klinisk Biokemi i Norden* 2012;**1**:22-31.
15. Brødbæk K, **Gøtze JP**. Fatal blødningskomplikation hos patient med akut nyresvigt behandlet med dabigatran. *DSKB Nyt* 2013;**1**:16-18.
16. Afzal S, Philips M, **Gøtze JP**. Antikoagulation og biokemisk monitorering anno 2015. *Klinisk Biokemi i Norden* 2015;**3**:18-22.
17. Albrechtsen J, **Gøtze JP**, Johnsen AH. Immuno-MALDI: En lovende metode til måling af peptider. *Klinisk Biokemi i Norden* 2016;**3**:16-19.
18. Rehfeld JF, **Gøtze JP**, Hilsted LM. Forskningskultur i klinisk biokemi. *Klinisk Biokemi i Norden* 2017;**4**:34-38.
19. **Gøtze JP**. Kardiovaskulær endokrinologi i klinisk biokemi. *Klinisk Biokemi i Norden* 2018;**3**:10-16.

20. Rehfeld JF, **Gøtze JP**. Kvalitetsbedømmelse af forskning: JIF versus DORA. *Ugeskr Laeger* 2019;**180**:2312-2313.

VI. Indlæg (16)

1. **Gøtze JP.** Jens F. Rehfelds 60-års-dag. *Ugeskr Laeger* 2001;**163**:7291.
2. Siersbæk Hansen L, **Gøtze JP.** *Ældre og Sundhed* 2002;**1**:14-15.
3. **Gøtze JP.** Fra spire til sten. *DSKB Nyt* 2009;**1**:22-23.
4. **Gøtze JP.** Krudtugler på stoffer. *Information* 2013;**29**:18-19.
5. **Gøtze JP.** Pausegymnastik. *Information* 2013;**34**:16-17.
6. **Gøtze JP.** Jeppe på fedtbjerget. *Information* 2013;**38**:14-15.
7. **Gøtze JP.** Drømmen og det lykkelige menneske. *Berlingske Tidende* 2014;**33**:25.
8. **Gøtze JP.** At dække et behov, der ikke er der. Eller? *dBIO* 2015;**10**:27.
9. **Gøtze JP.** Sundhedstyraniet skader vores børn. *Information* 2015;**51**:16-17.
10. Ørnstrup L, Laursten AK, Christiansen L, Hansen H, **Gøtze JP.** Stille, små mirakler. *dBIO* 2016;**6-7**:22-23.
11. **Gøtze JP.** Lucky Choices: En bog om livet med forskning af Jens Christian Skou. *Ugeskr Laeger* 2017: <http://ugeskriftet.dk/debat/lucky-choices>.
12. **Gøtze JP.** Natriuretiske peptider som knoglefremmende hormoner. *Ugeskr Laeger* 2017;**24**:2102.
13. **Gøtze JP.** Renal denervation beskytter hjertemuskulaturen gennem nedsat neprilysinaktivitet. *Ugeskr Laeger* 2017;**24**:2103.
14. **Gøtze JP.** B-type natriuretisk peptid som prognosemarkør hos patienter uden hjertesvigt. *Ugeskr Laeger* 2018;**14**:1227.
15. **Gøtze JP.** Hæmofili kan behandles med genterapi. *Ugeskr Laeger*, 2018;4:307.
16. **Gøtze JP.** Vejen fra Homo sapiens til Homo deus. *Politiken* 2018: 21. oktober.

VII. Patentansøgninger (3)

1. A processing-independent neuropeptide assay. Rehfeld JF, **Gøtze JP**. Offentliggjort den 11. april 2003 (WO03/087819).
2. Use of progastrin-derived peptides. Rehfeld JF, Bundgaard JR, **Gøtze JP**. Ansøgning indleveret den 6. februar 2004 (PA 2004 00180).
3. Peptide hormone with one or more O-glycans. Scholdager K, Clausen H, Hansen LH, **Gøtze JP**. Indleveret december 2017.

VIII. Udarbejdede eller indsendte manuskripter

1. **Gøtze JP**, Brødbæk K, Knigge U, Kristensen B, Hilsted LM. Comparison of immunoassays for chromogranin A measurement in plasma from patients with neuroendocrine neoplasms of the small intestine.
2. Hansen LH, Madsen TD, Goth DK, Vakhrushev SY, Clausen H, Burnett JC, Rehfeld JF, Schjoldager KT, **Gøtze JP**. Endogenous O-glycosylated atrial natriuretic peptide with preserved bioactivity.
3. Mark PD, Frydland M, Hassager C, **Gøtze JP**. Increased proCNP in plasma from patients presenting with ST-segment elevation myocardial infarction.
4. Albrechtsen NJW, Mark PD, Terzic D, Hansen LH, Andersen UØ, Hartmann B, Carr RD, Deacon CF, Holst JJ, **Gøtze JP**, Plomgaard PS. Sacubitril/valsartan increases postprandial glucagon-like peptide-1 concentrations and has synergistic effects when combined with sitagliptin.
5. Vøjdeman FJ, Philips M, Funding E, **Gøtze JP**. Diagnostik af von Willebrand sygdom.
6. Eskesen K, Sogaard P, Larsson H, **Gøtze JP**, Fritz-Hansen T, Olsen NT. Determinants of N-terminal pro-B-type natriuretic peptide levels and correlation with outcome in chronic aortic regurgitation.
7. Christensen HM, Kistorp C, Schou M, Keller N, Frystyk J, Flyvbjerg A, **Gøtze JP**, Faber J. Ongoing muscle wasting despite stable weight in cachectic heart failure patients: A prospective study.
8. Asferg CL, Andersen UB, Linneberg A, Hedley PL, Christiansen M, **Gøtze JP**, Esler M, Jeppesen J. Neuroendocrine markers associated with 24 hour ambulatory blood pressure in obese men.
9. Ambrus RB, Strandby RB, Achiam M, **Gøtze JP**, Fukuoma D, Secher N, Svendsen LB. Plasma atrial natriuretic peptide during abdominal surgery: A systematic review.
10. Valeur N, Ersboll M, Sogaard P, Hassager C, **Gøtze JP**, Kober L. Chromogranin A concentrations are associated with prognosis but not left ventricular systolic function in patients with myocardial infarction.
11. Rasmussen KC, Højskov M, Thind P, Ruhnau B, Sennels HP, Pedersen T, **Gøtze JP**, Secher NH. The stress response is attenuated during robot assisted radical cystectomy.
12. Zaar M, Petersen LG, Rokamp KZ, **Gøtze JP**, Johansson PI, Nielsen RV, Staalsø JM, Olsen NV, Nielsen HB, Secher NH. Effect of Arg16Gly α_2 -adrenergic receptor polymorphism on the hemostatic response to epinephrine in humans.
13. Langkilde A, Andersen O, Johansen IS, **Gøtze JP**, Eugen-Olsen J, Petersen J, Jeppesen J. Midregional proANP concentrations in HIV-infected patients: Associations with body composition, metabolism, and blood pressure.
14. Thomsen CF, Dreier R, Gohorian T, **Gøtze JP**, Andersen LB, Faber J, Ried-Larsen M, Grøntved A, Jeppesen JL. The association of copeptin, a surrogate marker for arginine vasopression, with components the metabolic syndrome in healthy adolescents and young adults from the general population.
15. Ichiki T, Lyer SR, Scott CG, Cannone V, Huntley BK, Sangaralingham SJ, Heubelin DM, Bailey KR, Rodeheffer R, **Gøtze JP**, Burnett Jr JC. Circulating corin in the general community: A link to gender and metabolic phenotype.
16. Frydland M, Møller JE, Lindholm MG, Hansen R, Wiberg S, Møller-Helgestad OK, Thomsen JH, **Gøtze JP**, Engstrøm T, Frikke-Schmidt R, Ravn HB, Holmvang L, Jensen LO, Kjærgaard J, Hassager C. Biomarkers predictive of late cardiogenic shock development in patients with suspected ST-elevation myocardial infarction.
17. Ersbøll A, **Gøtze JP**, Johansen M, Hauge MG, Vejlstrup NG, Silwa K, Gustafsson F, Damm P. Circulating concentrations of antiangiogenic and cardiac biomarkers associate with measures of diastolic dysfunction and maximal exercise capacity seven years after peripartum cardiomyopathy.
18. Strandby RB, Ambrus R, Henriksen A, Achiam MP, **Gøtze JP**, Secher NH, Svendsen LB. Plasma pro-atrial natriuretic peptide response to esophagectomy and to hypotensive hypovolemia in pigs: Influence of thoracic epidural anesthesia in randomized controlled trials.

19. Wiese S, Hove J, Mo S, Mygind ND, Tønnesen J, Petersen CL, Clemmensen O, **Gøtze JP**, Bendtsen F, Møller S. Cardiac dysfunction in cirrhosis: a 2-year follow-up study using advanced cardiac imaging.
20. Árnadóttir A, Pedersen S, **Gøtze JP**, Friis-Hansen LJ, Bloch-Münster AM, Jensen JS, Iversen K. Induced myocardial ischemia: serial measurements of cardiac troponin T, troponin I measured with high-sensitivity assays and copeptin (ICE-land).
21. Jonsdottir B, Severinsen MZ, San Miguel C, **Gøtze JP**, Melander O. ST2 predicts mortality in patients with acute hypercapnic respiratory failure treated with noninvasive positive pressure ventilation.
22. Falkentoft AC, Rørth R, Iversen K, Høfsten DE, Kelbæk H, Holmvang L, Frydland M, Schoos MM, Helquist S, Axelsson A, Clemmensen P, Tilsted HH, Pedersen F, Torp-Pedersen C, Kofoed KF, **Gøtze JP**, Engstrøm T, Køber L. Copeptin as a prognostic marker in patients with ST-segment elevation myocardial infarction – a Danami-3 substudy.
23. Lerche CJ, Christophersen LJ, **Gøtze JP**, Thomsen K, Enevold C, Højby N, Jensen PØ, Bundgaard H, Moser C. Adjunctive dabigatran treatment in experimental *Staphylococcus aureus* aortic valve endocarditis.
24. Højagergaard MA, Hassager C, Christensen TE, Bang LE, **Gøtze JP**, Ostrowski SR, Holmvang L, Frydland M. Biomarkers in patients with Takotsubo cardiomyopathy compared to patients with acute anterior ST-elevation myocardial infarction.